{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:27:11Z","timestamp":1792427231566,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtct.2024.07.025","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T06:06:19Z","timestamp":1722578779000},"page":"1003.e1-1003.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-0681","authenticated-orcid":false,"given":"Jhonny","family":"Carranza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-049X","authenticated-orcid":false,"given":"Giancarlo","family":"Fatobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Jun","family":"Otuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-116X","authenticated-orcid":false,"given":"Joaquim Gasparini","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Costa","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.07.025_bib0001","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2016.03.018","article-title":"Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes","volume":"22","author":"Flowers","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.07.025_bib0002","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jtct.2024.07.025_bib0003","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"8852","key":"10.1016\/j.jtct.2024.07.025_bib0004","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"The Lancet"},{"issue":"23","key":"10.1016\/j.jtct.2024.07.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2024.07.025_bib0006","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2016.1185785","article-title":"Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning","volume":"57","author":"Isidori","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.jtct.2024.07.025_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-018-0196-3","article-title":"High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.025_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-018-0328-9","article-title":"High-dose Benda-EAM versus BEAM in patients with relapsed\/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"54","author":"Tsang","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.07.025_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.12610","article-title":"Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: efficacy and toxicity","volume":"13","author":"Shi","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.025_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-016-2900-y","article-title":"BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients","volume":"96","author":"Gilli","year":"2017","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2024.07.025_bib0011","doi-asserted-by":"crossref","DOI":"10.1080\/1042819031000083028","article-title":"BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy","volume":"44","author":"Jantunen","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jtct.2024.07.025_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.07.025_bib0013","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1080\/10428194.2017.1403019","article-title":"A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience","volume":"59","author":"Saleh","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2024.07.025_bib0014","series-title":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","first-page":"1","year":"2017"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.025_bib0015","first-page":"1","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2024.07.025_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.025_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2010.07.016","article-title":"Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies","volume":"17","author":"Kebriaei","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.07.025_bib0018","article-title":"Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: A single center experience","volume":"8","author":"Berber","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"10","key":"10.1016\/j.jtct.2024.07.025_bib0019","article-title":"Oral and gut microbiota dysbiosis is associated with mucositis severity in autologous hematopoietic stem cell transplantation: evidence from an Asian population","volume":"29","author":"Wong","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2024.07.025_bib0020","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2015.1028054","volume":"56","author":"Sakellari","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.025_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13102","article-title":"High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity","volume":"101","author":"Noesslinger","year":"2018","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2024.07.025_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-019-0508-2","article-title":"High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients","volume":"54","author":"Prediletto","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.07.025_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25077","article-title":"Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers","volume":"93","author":"Chantepie","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.025_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2015.257","article-title":"Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity","volume":"51","author":"Garciaz","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.025_bib0025","article-title":"Impact of implementing a bendamustine-based conditioning regimen on outcomes of autologous stem cell transplantation in lymphoma while novel cellular therapies emerge","volume":"29","author":"Lachance","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2024.07.025_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-020-0783-y","article-title":"Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers","volume":"55","author":"Hueso","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.07.025_bib0027","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2024.07.025_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.07.025_bib0029","doi-asserted-by":"crossref","DOI":"10.1586\/17474086.2013.814451","article-title":"High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future","volume":"6","author":"Isidori","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.025_bib0030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","article-title":"BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: a single center comparative analysis of efficacy and toxicity","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk Res"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724005554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T18:05:13Z","timestamp":1759428313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724005554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666636724005554"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}